Medindia
Advertisement

New Drug Treatment for Ebola Virus Disease from Japan offers 'Hope'

by Shirley Johanna on March 2, 2015 at 4:10 PM
Font : A-A+

New Drug Treatment for Ebola Virus Disease from Japan offers 'Hope'

An experimental Ebola treatment by a Japanese company says it is "not a miracle drug", but offers new hope for thousands of people infected with the deadly virus in west Africa.

In their first comments to media since the release of early clinical trials last week, executives from Fujifilm's drug unit Toyama Chemical said the results were a "good first step" that could lead to larger and better-designed trials.

Advertisement

Avigan -- approved for use in Japan as an influenza treatment -- was somewhat effective at saving the lives of Ebola patients if given early in the illness, but not later, according to the results presented to a US conference.

"They were better than my expectations," Fujifilm director Yuzo Toda said in an interview at the company's office in Tokyo.

"Taking this medicine as early as possible (means) the mortality rate can be significantly reduced. That sends a very strong message to the patient."
Advertisement

Testing began late last year, led by INSERM, the French Institute of Health and Medical Research, and is being funded by the European Commission.

The ongoing clinical trial in hard-hit Guinea -- dubbed Jiki, meaning hope in the local language -- is testing the drug on patients with Ebola, which causes severe vomiting, diarrhoea and sometimes fatal bleeding.

Results from only 80 people are available so far, but they show that among those who received the drug early in their illness, 15 percent died.

However, among those who received it when their viral load was high, 93 percent died, according to the preliminary results presented at the Conference on Retroviruses and Opportunistic Infections in Seattle, Washington.

No Help for Most Vulnerable

There are no drugs on the market to treat Ebola, which has ravaged west Africa and killed 9,177 of the nearly 23,000 people infected since late 2013. Clinical trials of other experimental drugs are under way but are at an earlier stage.

The death rate from the virus in the latest outbreak has ranged from 53 to 60 percent, according to the World Health Organization.

NGO Medecins Sans Frontieres (Doctors Without Borders), which is among those helping to carry out the trial, said it was happy to see the drug "seems to have a positive effect for certain patients".

"But it also seems that the most vulnerable patients, the people that are most likely to die from the disease, don't benefit at all," said the group's medical director Bertrand Draguez.

Toda and his colleagues acknowledged the drug's apparent limitations, but said any positive results could help spread the word among the worst-hit communities and convince more patients to sign up for clinical trials.

They hope the WHO will accelerate the use of Avigan to deal with the Ebola crisis.

"We didn't expect it would work for all patients, or be a miracle drug, but this is a very good first step," said Hiroshi Kitaguchi, general manager of the business development unit at Toyama Chemical, which developed Avigan.

"The results may not be a miracle, but we can say it is a miracle that we have (come) this far in such a short period of time."

Best known for its photo film and camera business, Fujifilm started to acquire healthcare firms nearly a decade ago in a bid to branch into other sectors as demand for camera film plummeted. Among them was Toyama Chemical, which it bought in 2008.

Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Gonorrhea
World Alzheimer's Day 2021 - 'Know Dementia, Know Alzheimer's
'Hybrid Immunity' may Help Elude COVID-19 Pandemic
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Chicken Pox Drug Toxicity Shigellosis Clinical Trials - Different Phases of the trial Bioterrorism Signature Drug Toxicity Congo Fever Ebola Virus Disease 

Recommended Reading
Early Results from Ebola Drug Trial Shows Limited Promise
Early results from an Ebola trial using Avigan (favipiravir), the experimental drug, showed that it ...
US Company Says It Has Shipped All Available Doses of Its Experimental Ebola Drug to West Africa
An American company has confirmed that it has shipped all available doses of its experimental drug, ...
Ethics Meeting Over Experimental Ebola Drug Called by WHO
An ethics meet to explore the use of experimental treatment in the Ebola outbreak in West Africa ......
Experimental Ebola Drug too Early to be Sent to Africa: Obama
US President Barack Obama claims on Wednesday that it is "premature" to send experimental drugs for ...
Chicken Pox
Chicken pox is an acute and highly contagious viral infection caused by the varicella zoster virus....
Clinical Trials - Different Phases of the trial
Clinical trials serve as a vital component for improving the treatment of medical conditions as they...
Congo Fever
Crimean-Congo Hemorrhagic fever (CCHF) is a viral disease that affects people who are bitten by infe...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Ebola Virus Disease
Ebola is caused by a virus via direct contact with body fluids or infected blood. Scientists have id...
Shigellosis
Shigellosis or Bacillary Dysentery is a common cause of gastro-enteritis worldwide and can cause blo...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use